Want to see RANI full AI Analyst Report?
RANI Stock Chart & Stats
$0.85
-$0.04(-4.79%)
At close: 4:00 PM EDT
$0.85
-$0.04(-4.79%)
Day’s Range― - ―
52-Week Range$0.44 - $3.87
Previous Close$0.82
Volume837.84K
Average Volume (3M)910.20K
Market Cap
$122.67M
Enterprise Value$101.03
Total Cash (Recent Filing)$53.39M
Total Debt (Recent Filing)$3.55M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Nov 05, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding115,424,960
10 Day Avg. Volume1,465,082
30 Day Avg. Volume910,200
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.70
Price to Sales (P/S)54.68
P/FCF Ratio-4.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.75Price Target Upside694.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$4.13M
Bulls Say, Bears Say
Bulls Say
RaniPill Clinical ValidationPositive human data support the core platform’s ability to deliver biologics orally, potentially improving convenience and adherence. Further dose-expansion data could strengthen partnering prospects and validate broader use across injectable therapies.
Revenue Growth And Gross MarginRapid revenue growth and very high gross margin indicate improving monetization of collaborations and favorable economics on current activities. Sustained program funding or licensing growth could provide operating leverage as the pipeline advances.
Low Balance-Sheet LeverageLow debt relative to equity limits interest and refinancing pressure, giving Rani greater flexibility to fund clinical development. This is a meaningful structural improvement from 2024, when leverage was materially higher.
Bears Say
Persistent Operating LossesRani remains far from operating break-even despite revenue improvement. Very large losses can consume capital, weaken equity value, and require continued execution or financing before the platform can support a self-sustaining business.
Continued Cash BurnNegative operating and free cash flow show that current programs are not self-funding. Until revenue scales or development spending narrows, Rani will remain reliant on external capital, increasing financial and execution risk.
Clinical-Stage Partnership DependenceThe business lacks an established product-sales base and depends on partners and clinical milestones to generate durable revenue. Delays, trial setbacks, or weaker partnering activity could materially postpone commercialization and cash generation.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings, Inc. Class A’s price range in the past 12 months?
Rani Therapeutics Holdings, Inc. Class A lowest stock price was $0.44 and its highest was $3.87 in the past 12 months.
What is Rani Therapeutics Holdings, Inc. Class A’s market cap?
Rani Therapeutics Holdings, Inc. Class A’s market cap is $122.67M.
When is Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date?
Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date is Nov 05, 2026 which is in 72 days.
How were Rani Therapeutics Holdings, Inc. Class A’s earnings last quarter?
Rani Therapeutics Holdings, Inc. Class A released its earnings results on Aug 14, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.01.
Is Rani Therapeutics Holdings, Inc. Class A overvalued?
According to Wall Street analysts Rani Therapeutics Holdings, Inc. Class A’s price is currently Undervalued.
Does Rani Therapeutics Holdings, Inc. Class A pay dividends?
Rani Therapeutics Holdings, Inc. Class A does not currently pay dividends.
What is Rani Therapeutics Holdings, Inc. Class A’s EPS estimate?
Rani Therapeutics Holdings, Inc. Class A’s EPS estimate is -0.05.
How many shares outstanding does Rani Therapeutics Holdings, Inc. Class A have?
Rani Therapeutics Holdings, Inc. Class A has 115,424,960 shares outstanding.
What happened to Rani Therapeutics Holdings, Inc. Class A’s price movement after its last earnings report?
Rani Therapeutics Holdings, Inc. Class A reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went down -0.125%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings, Inc. Class A?
Currently, no hedge funds are holding shares in RANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.75 (694.12% Upside)
$6.75 (694.12% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 57.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
69.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
260.06%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
RANI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.View all RANI earnings summariesRANI Stock 12 Month Forecast
Average Price Target
$6.75
▲(694.12% Upside)
Technical Analysis
Ownership Overview
24.07% Insiders
4.72% Mutual Funds
30.48% Other Institutional Investors
36.72% Public Companies and
Individual Investors